Undisclosed bispecific ADC
/ Veraxa Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
An avidity-driven, dual-targeting ADC with superior tumor selectivity for the treatment of solid tumors
(AACR 2026)
- "This enables the application of a potent PBD prodrug for highly efficient anti-tumor activity. Our lead bsADC for the treatment of lung and breast cancers has entered formal preclinical development and IND-enabling studies."
ADC • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
1 to 1
Of
1
Go to page
1